Plain-English translation of NCT07103668 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new treatment called IMC002, which is a type of cell therapy designed to fight stomach cancer. The study will compare IMC002 to standard chemotherapy options that your doctor would normally choose. You are eligible if your cancer has already been treated with at least two prior therapy lines and has not responded well.
Advanced stomach cancer that has progressed despite multiple prior treatments is very difficult to manage, and patients urgently need new options beyond standard chemotherapy. This trial exists to see whether this medication, which works in a different way than conventional drugs, might help patients whose cancer has become resistant to earlier treatments.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either IMC002 or your doctor's choice of standard chemotherapy. The trial is open-label, meaning you and your doctor will know which treatment you are receiving. You will have regular clinic visits for treatment administration, blood tests to monitor your health and blood cell counts, and imaging scans to track how your cancer responds. The study will follow you for at least 12 weeks or longer depending on how well the treatment works.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China